Home
Mintz
Joanne S. Hawana
Joanne S. Hawana
Mintz
FDA Begins Modernizing Its Resources And Implementing Over-The-Counter Monograph User Fee Requirements
18 Oct 2021 | United States
FDA And FTC Coordination Appears To Be Escalating
17 Sep 2021 | United States
Biden Administration's Drug Pricing Plan Calls For Bold Action By Congress
13 Sep 2021 | United States
Ushering In A New Era: FDA Approves First Interchangeable Biosimilar
05 Aug 2021 | United States
Bipartisan VALID Act Re-Introduced In Congress: Is Diagnostics Reform On The Horizon?
14 Jul 2021 | United States
FDA's Unapproved Drugs Initiative Revived, With Gusto!
11 Jun 2021 | United States
Health Law Diagnosed — Hot Topics In FDA Regulation And Enforcement
17 May 2021 | United States
FDA Ups The Ante And Sends First Notice Of Noncompliance For Failure To Submit Clinical Trial Results
07 May 2021 | United States
FDA Releases Ambitious Action Plan For Further Reducing Children's Exposure To Toxic Elements From Foods
29 Apr 2021 | United States
FTC Engages In First Enforcement Action Under COVID-19 Consumer Protection Act
29 Apr 2021 | United States
FDA's Biologics Inspections In The (Negative) Limelight: Will Congress Or Executive Leadership Take Action?
09 Apr 2021 | United States
Recent Amendments To The FDA Laws Attempt To Clarify And Improve Existing Systems
29 Jan 2021 | United States
FDA In 2020: What A Year! (Part 3 Of 3)
28 Dec 2020 | United States
FDA In 2020: What A Year! (Part 2 Of 3)
24 Dec 2020 | United States
DEA Releases Long-Awaited Suspicious Orders Proposed Rule
14 Nov 2020 | United States
An Update On FDA's Contribution To COVID-19 Diagnostic Testing
11 Nov 2020 | United States
FDA's Prescription Drug Advertising Enforcers Issue COVID-19-Related Warning Letter
07 Oct 2020 | United States
Final Canadian Drug Importation Rule And HHS Certification Issued Under Section 804 Of The Food, Drug And Cosmetic Act
29 Sep 2020 | United States
OTC Monograph Reform: Key Takeaways And What Industry Can Expect
25 Aug 2020 | United States
With Release Of New Guidance, FDA Signals It's Serious About Enforcing Clinical Trial Data Requirements
24 Aug 2020 | United States
< 1 2 3 4 5 6 7 8 9 >
20%
Very Popular: This author falls within the Top 20% for the below topics and industry categories
Based on Mondaq users readership, this author is ranked as VERY POPULAR in United States for the topics, user groups and industry sectors listed below*:
Topics
  • Product Liability & Safety
  • Consumer Protection
  • Life Sciences, Biotechnology & Nanotechnology
Industry
  • Chemicals
  • Media & Information
* Rankings are based on analysis of the last 12 months of Mondaq readership data across more than 25,000 contributing authors. To be ranked ‘Very Popular’ an author must be in the top 20% of results within the selected criteria.
Contact Details
Washington, DC
Email Website
One Financial Center
Washington, DC
United States
Telephone: 1-617-5426000

  © Mondaq® Ltd 1994 - 2021. All Rights Reserved.